IP Library Patent Application 14951290
Patent Application
App. No. 14/951,290

METHOD FOR INHIBITING CELL GROWTH USING ANTI-ERBB-3 ANTIBODIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/951,290
Abstract

Methods for arresting or inhibiting cell growth, particularly cancer cell growth, comprising preventing or reducing ErB-2/ErbB-3 heterodimer formation, or interfering with ErB-2/ErbB-3 heterodimer conformation in a cell and agents which prevent or reduce ErB-2/ErbB-3 heterodimer formation or interface with ErB-2/ErbB-3 heterodimer conformation in a cell thereby arresting or inhibiting the growth of the cell.

Claims (13)

1 - 26 . (canceled)

27 . A method of arresting or inhibiting cell growth comprising contacting an ErbB-2 over-expressing cell with an anti-ErbB-3 antibody, thereby arresting or inhibiting growth of said ErbB-2 over-expressing cell.

28 . The method of claim 27 , wherein the anti-ErbB-3 antibody is H3.105.5.

29 . The method of claim 27 , wherein the anti-ErbB-3 antibody is a monoclonal antibody.

30 . The method of claim 29 , wherein the monoclonal antibody is humanized.

31 . The method of claim 27 , wherein the cell is a cancer cell.

32 . The method of claim 31 , wherein the cancer cell is a human breast cancer cell.

33 . The method of claim 32 , wherein the human breast cancer cell is SK-BR-3, MDA-MB-453, or BT-474.

34 . A method for treating ErbB-2 over-expressing cancer, comprising administering to a subject in need thereof a composition comprising an anti-ErbB-3 antibody, thereby treating ErbB-2 over-expressing cancer in said subject.

35 . The method of claim 34 , wherein the anti-ErbB-3 antibody is H3.105.5.

36 . The method of claim 34 , wherein the anti-ErbB-3 antibody is a monoclonal antibody.

37 . The method of claim 36 , wherein the monoclonal antibody is humanized.

38 . The method of claim 34 , wherein the cancer is a human breast cancer.

Assignments (1)
CHANGE OF NAME Recorded Jun 8, 2016
From: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, LTD.
To: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, CO., LTD.
Reel/Frame 038925/0398 →